Evidence map›Paper›PMID 19503797›Full record

ArticlePloS one2009

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Carla Maria P Ribeiro, Harry Hurd, Yichao Wu, Mary E B Martino, Lisa Jones, Brian Brighton, Richard C Boucher, Wanda K O'Neal

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03045198 (Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis), which is not on this map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03045198 phase4unknown statusnot on this mapstarted 2012, after this paper: background citation

Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis

TypeinterventionalSponsorUniversity Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)Ran2012 to 2018Enrolled20ConditionsCystic FibrosisArmsAzithromycin
3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. IRE1α Is a Therapeutic Target for Cystic Fibrosis Airway Inflammation.International journal of molecular sciences · 2021
    Article
  12. Azithromycin in viral infections.Reviews in medical virology · 2021
    Review
  13. Airway Epithelial InflammationFrontiers in pharmacology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carla Maria P RibeiroCystic Fibrosis Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. carla_ribeiro@med.unc.edu
Harry Hurd
Yichao Wu
Mary E B Martino
Lisa Jones
Brian Brighton
Richard C Boucher
Wanda K O'Neal

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolonged macrolide antibiotic therapy at low doses improves clinical outcome in patients affected with diffuse panbronchiolitis and cystic fibrosis. Consensus is building that the therapeutic effects are due to anti-inflammatory, rather than anti-microbial activities, but the mode of action is likely complex. To gain insights into how the macrolide azithromycin (AZT) modulates inflammatory responses in airways, well-differentiated primary cultures of human airway epithelia were exposed to AZT alone, an inflammatory stimulus consisting of soluble factors from cystic fibrosis airways, or AZT followed by the inflammatory stimulus. RNA microarrays were conducted to identify global and specific gene expression changes. Analysis of gene expression changes revealed that the AZT treatment alone altered the gene profile of the cells, primarily by significantly increasing the expression of lipid/cholesterol genes and decreasing the expression of cell cycle/mitosis genes. The increase in cholesterol biosynthetic genes was confirmed by increased filipin staining, an index of free cholesterol, after AZT treatment. AZT also affected genes with inflammatory annotations, but the effect was variable (both up- and down-regulation) and gene specific. AZT pretreatment prevented the up-regulation of some genes, such as MUC5AC and MMP9, triggered by the inflammatory stimulus, but the up-regulation of other inflammatory genes, e.g., cytokines and chemokines, such as interleukin-8, was not affected. On the other hand, HLA genes were increased by AZT. Notably, secreted IL-8 protein levels did not reflect mRNA levels, and were, in fact, higher after AZT pretreatment in cultures exposed to the inflammatory stimulus, suggesting that AZT can affect inflammatory pathways other than by altering gene expression. These findings suggest that the specific effects of AZT on inflamed and non-inflamed airway epithelia are likely relevant to its clinical activity, and their apparent complexity may help explain the diverse immunomodulatory roles of macrolides.

Indexed as

Gene Expression RegulationAnti-Bacterial AgentsAzithromycinCell CycleEpithelial CellsGene Expression ProfilingHumansInflammationInterleukin-8Lipid MetabolismLipidsLungMatrix Metalloproteinase 9Mucin 5ACPseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial AgentsAzithromycinInterleukin-8LipidsMatrix Metalloproteinase 9MUC5AC protein, humanMucin 5AC

Identifiers

PMID19503797
PMCPMC2688381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.